
Home / News
-
-
-
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025.2025-07-23View More
-
-
-
-
1.2 Cardiovascular Diseases (Cardiac Markers) Cardiovascular disease remains the leading cause of death worldwide. More than half a billion people around the world continue to be affected by cardiovascular disea..2025-07-22View More
-
-
-
-
Orient Gene's Respiratory Multiplex Tests Get Approved in New Zealand and Brazil Recently, some partner clients of Orient Gene have obtained registration approval from New Zealand¡¯s Medsaf..2025-07-22View More
-
-
-
-
Shares of Oxford Nanopore Technologies jumped 16 percent on Monday after the company reported strong preliminary revenues for the first half of 2025.2025-07-22View More
-
-
-
-
The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of $2.4 million for the development of saliva-based liquid biopsy technologies.2025-07-22View More
-
-
-
-
One Biosciences, a French startup pursuing single-cell tumor RNA sequencing, said on Thursday that it has raised €15 million ($17.4 million) Series A financing.2025-07-21View More
-
-
-
-
President Donald Trump's proposed budget cuts to the National Institutes of Health would eventually result in fewer drugs on the market, the U.S. Congressional Budget Office said on Friday.2025-07-21View More
-
-
-
-
Fulgent Genetics announced on Thursday that it has obtained the CE-IVDR mark for its germline next-generation sequencing service.2025-07-18View More
-
-
-
-
Original from: Abbott Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2025. ¡¤ Second-quarter sales increased 7.4 percent on a reported basis, 6.9..2025-07-18View More
-
-
-
-
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed.2025-07-17View More
-
-
-
-
To the cheers of blood centers, the US Food and Drug Administration said this week that it plans to eliminate a requirement to screen donated blood with hepatitis B virus surface antigen testing when two other testing methods are also used.2025-07-17View More
-
-
-
-
Original from: National Bureau of Statistics of China National Bureau of Statistics of China 15 July, 2025 In the first half year, under the strong leadership of the Central Committee of the ..2025-07-16View More
-
-
-
-
On 10 July 2025, the World Health Organization (WHO) prequalified the first bundled set of three in vitro rapid diagnostic tests (RDTs) capable of simultaneously detecting HIV, hepatitis B virus (HBV) and syphilis ¨C three major infections that pose serious risks to maternal and child health.2025-07-16View More
-
-
-
-
1.1 Blood Glucose The latest IDF Diabetes Atlas (2025) reports that diabetes affects 589 million adults (20-79 years) around the world in 2024, with over 4 in 10 unaware that they have the condition. Over 4 in 5..2025-07-15View More
-
-
-
-
PerkinElmer Launches New R&D and Manufacturing Base in China On July, PerkinElmer officially inaugurated its new Taicang-based R&D and manufacturing base, global procurement center..2025-07-15View More
-
-
-
-
QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.2025-07-15View More
-
-
-
-
Original from: Waters ¡¤ Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters¡¯ proven execution model ¡¤ Doubles Wate..2025-07-15View More
-
-
-
-
Personalis said this week that it has extended its strategic collaboration with Tempus AI to include colorectal cancer (CRC) among the indications covered by their existing, exclusive commercialization agreement.2025-07-14View More
-
-
-
-
Claret Bioscience, a pioneer in next-generation sequencing (NGS) library preparation technologies for challenging samples, and Hamilton Company, a global leader in precision laboratory automation, are proud to announce a strategic co-promotion initiative. This collaboration aims to accelerate and simplify workflows for throughput NGS library preparation by delivering validated automation protocols for ClaretBio¡¯s SRSLY® and REALLY™ product lines on Hamilton¡¯s NGS STAR liquid handling platforms.2025-07-14View More
-
-
China NMPA Announces New Measures to Boost High-End Medical Device Innovation and Regulatory Support
-
-
The National Medical Products Administration (NMPA) of China has introduced a series of strategic measures to accelerate the development of new-quality productivity in the high-end medical device sector.2025-07-11View More
-
- CAIVD WeChat
Subscription Account
- CAIVD WeChat
Channels
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.